Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Albert Tran

Showing results (171-180 of 181) with videos related to

Pageof 19
Sort By:
Gastroenterology|April 8, 2014
Effectiveness of telaprevir or boceprevir in treatment-experienced patients with HCV genotype 1 infection and cirrhosisChristophe Hézode, Helene Fontaine, Celine Dorival, et al.
Hepatology (Baltimore, Md.)|February 14, 2015
Complications and competing risks of death in compensated viral cirrhosis (ANRS CO12 CirVir prospective cohort)Jean-Claude Trinchet, Valérie Bourcier, Cendrine Chaffaut, et al.
Journal of Hepatology|July 3, 2020
Personalized surveillance for hepatocellular carcinoma in cirrhosis - using machine learning adapted to HCV statusEtienne Audureau, Fabrice Carrat, Richard Layese, et al.
Gastroenterology|July 22, 2018
Incidence of Hepatocellular Carcinoma After Direct Antiviral Therapy for HCV in Patients With Cirrhosis Included in Surveillance ProgramsPierre Nahon, Richard Layese, Valérie Bourcier, et al.
Gastroenterology|February 16, 2019
Validation of Baveno VI Criteria for Screening and Surveillance of Esophageal Varices in Patients With Compensated Cirrhosis and a Sustained Response to Antiviral TherapyDominique Thabut, Christophe Bureau, Richard Layese, et al.
Gastroenterology|May 6, 2018
Compliance With Hepatocellular Carcinoma Surveillance Guidelines Associated With Increased Lead-Time Adjusted Survival of Patients With Compensated Viral Cirrhosis: A Multi-Center Cohort StudyCharlotte E Costentin, Richard Layese, Valérie Bourcier, et al.
Hepatology (Baltimore, Md.)|April 18, 2018
Extrahepatic cancers are the leading cause of death in patients achieving hepatitis B virus control or hepatitis C virus eradicationManon Allaire, Pierre Nahon, Richard Layese, et al.
Gut|October 30, 2015
Bacterial infection in compensated viral cirrhosis impairs 5-year survival (ANRS CO12 CirVir prospective cohort)Pierre Nahon, Mathilde Lescat, Richard Layese, et al.
Gastroenterology|September 20, 2016
Eradication of Hepatitis C Virus Infection in Patients With Cirrhosis Reduces Risk of Liver and Non-Liver ComplicationsPierre Nahon, Valérie Bourcier, Richard Layese, et al.
American Heart Journal|April 15, 2018
Prognostic value of viral eradication for major adverse cardiovascular events in hepatitis C cirrhotic patientsPatrice Cacoub, Pierre Nahon, Richard Layese, et al.
Pageof 19

Showing results (171-180 of 181) with videos related to

Sort By:
Pageof 19
Gastroenterology|April 8, 2014
Effectiveness of telaprevir or boceprevir in treatment-experienced patients with HCV genotype 1 infection and cirrhosisChristophe Hézode, Helene Fontaine, Celine Dorival, et al.
Hepatology (Baltimore, Md.)|February 14, 2015
Complications and competing risks of death in compensated viral cirrhosis (ANRS CO12 CirVir prospective cohort)Jean-Claude Trinchet, Valérie Bourcier, Cendrine Chaffaut, et al.
Journal of Hepatology|July 3, 2020
Personalized surveillance for hepatocellular carcinoma in cirrhosis - using machine learning adapted to HCV statusEtienne Audureau, Fabrice Carrat, Richard Layese, et al.
Gastroenterology|July 22, 2018
Incidence of Hepatocellular Carcinoma After Direct Antiviral Therapy for HCV in Patients With Cirrhosis Included in Surveillance ProgramsPierre Nahon, Richard Layese, Valérie Bourcier, et al.
Gastroenterology|February 16, 2019
Validation of Baveno VI Criteria for Screening and Surveillance of Esophageal Varices in Patients With Compensated Cirrhosis and a Sustained Response to Antiviral TherapyDominique Thabut, Christophe Bureau, Richard Layese, et al.
Gastroenterology|May 6, 2018
Compliance With Hepatocellular Carcinoma Surveillance Guidelines Associated With Increased Lead-Time Adjusted Survival of Patients With Compensated Viral Cirrhosis: A Multi-Center Cohort StudyCharlotte E Costentin, Richard Layese, Valérie Bourcier, et al.
Hepatology (Baltimore, Md.)|April 18, 2018
Extrahepatic cancers are the leading cause of death in patients achieving hepatitis B virus control or hepatitis C virus eradicationManon Allaire, Pierre Nahon, Richard Layese, et al.
Gut|October 30, 2015
Bacterial infection in compensated viral cirrhosis impairs 5-year survival (ANRS CO12 CirVir prospective cohort)Pierre Nahon, Mathilde Lescat, Richard Layese, et al.
Gastroenterology|September 20, 2016
Eradication of Hepatitis C Virus Infection in Patients With Cirrhosis Reduces Risk of Liver and Non-Liver ComplicationsPierre Nahon, Valérie Bourcier, Richard Layese, et al.
American Heart Journal|April 15, 2018
Prognostic value of viral eradication for major adverse cardiovascular events in hepatitis C cirrhotic patientsPatrice Cacoub, Pierre Nahon, Richard Layese, et al.
Pageof 19